Publications
| 2006-04-06 |
New data on Bivalent Dengue Virus Vaccine using GenPhar's CAdVax platform is published. |
| Induction of bivalent immune response by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. |
| Am J Trop Med Hyg. 2007 Apr;76(4):743-51. Click here for full pdf of publication |
| About GenPhar, Inc. GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us. |


print this page
site map